Compare BridgeBio Pharma Inc (BBIO) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nasdaq Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Nasdaq Inc trades at $94.71 (market cap $53.11B). The key difference: Nasdaq Inc is far larger — about 3.2× BridgeBio Pharma Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | NDAQ | |
|---|---|---|
Market Cap | $16.36B | $53.11B |
Sector | Health | Financials |
52-Week High | $90.17 | $100.98 |
52-Week Low | $47.29 | $76.85 |
Enterprise Value | $18.14B | $59.57B |
Dividend Yield | — | 1.22% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
